Assertio Holdings Inc is a United States-based commercial pharmaceutical company. The Company focused on the marketing and distribution of branded prescription medicines across several therapeutic categories. It maintains a portfolio that includes treatments for neurology disorders, inflammatory conditions, pain management, and oncology. Its activities involve acquiring, licensing, and integrating approved pharmaceutical products, followed by commercialization within the healthcare market. Its operating approach centers on identifying products that have established regulatory clearance and advancing their reach through targeted sales, medical education, and market access efforts. It manages product lifecycles through activities such as labeling updates, supply coordination, and engagement with healthcare professionals and payers.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq 01:30:00 16/06/2026 am IST			5-day change	1st Jan Change
23.50 ^USD	+0.09%		-.--%	+159.10%

17/06	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
17/06	Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026	CI

Market Cap	15Cr 13Cr 12Cr 11Cr 21Cr 1.45TCr 21Cr 147.14Cr 57Cr 738.11Cr 57Cr 56Cr 2.33TCr	P/E 2024	-3.79x	P/E 2025	-1.91x
Enterprise Value	13Cr 11Cr 11Cr 9.52Cr 18Cr 1.23TCr 18Cr 124.71Cr 48Cr 625.58Cr 48Cr 47Cr 1.98TCr	EV / Sales 2024	0.19x	EV / Sales 2025	0.3x
Free-Float	99.05%	Yield 2024 *	-	Yield 2025	-

17/06	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
17/06	Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026	CI
16/06	Assertio Holdings, Inc.(NasdaqCM:ASRT) dropped from S&P TMI Index	CI
16/06	Assertio Holdings, Inc.(NasdaqGM:ASRT) dropped from NASDAQ Composite Index	CI
16/06	Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc..	CI
13/05	Garda Therapeutics, Inc. cancelled the acquisition of Assertio Holdings, Inc..	CI
13/05	Zydus Worldwide DMCC entered into definitive agreement to acquire Assertio Holdings, Inc. for approximately $160 million.	CI
13/05	Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash	RE
13/05	Assertio Board Approves $23.50-Per-Share Sale to Zydus Worldwide DMCC	MT
13/05	Zydus to Acquire Assertio for $166.4 Million	DJ
09/05	Assertio Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	Assertio and Garda mutually agree to delay launch of tender offer	RE
05/05	Assertio and Garda mutually agree to postpone commencement of tender offer	RE

09/04	HC Wainwright Downgrades Assertio Holdings to Neutral From Buy, Adjusts Price Target to $18 From $35	MT
03/24/03	HC Wainwright Initiates Assertio Holdings at Buy With $4 Price Target	MT
12/24/12	Lake Street Adjusts Assertio Therapeutics' Price Target to $3 From $4, Maintains Buy Rating	MT
10/23/10	BWS Financial Adjusts Assertio Therapeutics' Price Target to $10 From $8, Keeps Buy Rating	MT
10/23/10	Lake Street Adjusts Assertio Therapeutics' Price Target to $9 From $8, Keeps Buy Rating	MT

Assertio Holdings Share Price

Stocks

ASRT

US04546C3043

Pharmaceuticals

Valuation : Assertio Holdings

Chart: Assertio Holdings

Latest news : Assertio Holdings

Last Transcript : Assertio Holdings

Analysts' recommendations : Assertio Holdings

Press Releases : Assertio Holdings

Quotes and Performance

Price Extremes

Managers and Directors : Assertio Holdings

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

17/06	Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027	BU
19/05	Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT	BU
13/05	Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash	BU
08/05	Assertio and Garda Mutually Agree to Delay Launch of Tender Offer	BU
05/05	Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer	BU

1 day	+0.09%
3 months	+0.09%
6 months	+102.06%
Current year	+159.10%

Current year	9.11	23.5
1 year	8.61	23.5
3 years	7.71	45.9
5 years	7.71	120.15
10 years	7.71	1,621.19

Director	Title	Age	Since
Ravi Yadavar BRD	Director/Board Member	26	16/06/2026
Punit Patel BRD	Director/Board Member	-	16/06/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
13/05/26	Heather Mason	Don	Chairman	-13,332	0.2069%
05/05/26	Heather Mason	Free	Chairman	4,851	0.0753%
05/05/26	William McKee	Free	Director	4,851	0.0753%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ASSERTIO HOLDINGS	+0.09%	-.--%	+94.57%	-50.58%	15Cr
ELI LILLY AND COMPANY	+0.03%	-2.18%	+48.66%	+88.78%	1,00100Cr
JOHNSON & JOHNSON	-0.24%	-3.40%	+48.94%	+63.45%	64TCr
ABBVIE INC.	+0.94%	+0.42%	+16.94%	+72.79%	45TCr
ROCHE HOLDING AG	-0.38%	-3.59%	+28.24%	+35.57%	34TCr
NOVARTIS AG	-0.09%	-13.54%	+10.08%	+26.87%	26TCr
ASTRAZENECA PLC	-0.43%	-2.48%	-2.07%	+11.48%	25TCr
AMGEN INC.	-0.71%	-13.09%	+34.40%	+45.19%	21TCr
NOVO NORDISK A/S	-3.44%	-7.51%	-20.08%	-59.58%	20TCr
GILEAD SCIENCES, INC.	-0.61%	-4.61%	+22.21%	+86.97%	18TCr
Average	-0.46%	-4.94%	+28.19%	+32.09%	35.26TCr
Weighted average by Cap.	-0.23%	-4.65%	+30.25%	+56.03%

	2024	2025
Net sales	12Cr 11Cr 10Cr 9.24Cr 17Cr 1.19TCr 17Cr 121.08Cr 47Cr 607.36Cr 47Cr 46Cr 1.92TCr	12Cr 10Cr 9.68Cr 8.78Cr 16Cr 1.13TCr 17Cr 115.03Cr 44Cr 577Cr 45Cr 44Cr 1.82TCr
Net income	-2.16Cr -1.86Cr -1.76Cr -1.6Cr -2.99Cr -206.17Cr -3.01Cr -21Cr -8.04Cr -104.89Cr -8.1Cr -7.93Cr -331.45Cr	-3.04Cr -2.62Cr -2.48Cr -2.25Cr -4.21Cr -290.19Cr -4.24Cr -29Cr -11Cr -147.64Cr -11Cr -11Cr -466.51Cr
Net Debt	-5.98Cr -5.15Cr -4.88Cr -4.42Cr -8.29Cr -571.19Cr -8.34Cr -58Cr -22Cr -290.59Cr -22Cr -22Cr -918.25Cr	-2.32Cr -1.99Cr -1.89Cr -1.71Cr -3.21Cr -221.18Cr -3.23Cr -22Cr -8.63Cr -112.53Cr -8.69Cr -8.5Cr -355.58Cr